Covid19-Sources

4472 bookmarks
Newest
(6) Eric Topol auf Twitter: "New @TheLancet: @AstraZeneca vaccine vs B.1.1.7 strain (and non-B.1.1.7) in > 8500 participants w/ > 200,000 nose/ throat swabs https://t.co/1qsyvnJP9u Efficacy: Symptomatic B.1.1.7: 70%; other 82% Asymptomatic B.1.1.7:29%; other 70% https://t.co/oTQX9f9IbQ" / Twitter
(6) Eric Topol auf Twitter: "New @TheLancet: @AstraZeneca vaccine vs B.1.1.7 strain (and non-B.1.1.7) in > 8500 participants w/ > 200,000 nose/ throat swabs https://t.co/1qsyvnJP9u Efficacy: Symptomatic B.1.1.7: 70%; other 82% Asymptomatic B.1.1.7:29%; other 70% https://t.co/oTQX9f9IbQ" / Twitter
fsnestel·twitter.com·
(6) Eric Topol auf Twitter: "New @TheLancet: @AstraZeneca vaccine vs B.1.1.7 strain (and non-B.1.1.7) in > 8500 participants w/ > 200,000 nose/ throat swabs https://t.co/1qsyvnJP9u Efficacy: Symptomatic B.1.1.7: 70%; other 82% Asymptomatic B.1.1.7:29%; other 70% https://t.co/oTQX9f9IbQ" / Twitter
(3) Dr Nisreen Alwan 🌻 auf Twitter: "THREAD 1/ Our #LongCovid survey findings are now out. I want to express sincere thanks to all the participants. This study is from & for you. Apologies for the delay in reporting due to limited time & capacity but here we are (preprint, not peer reviewed) https://t.co/y7l60hqYnf https://t.co/iHSQYC1bT3" / Twitter
(3) Dr Nisreen Alwan 🌻 auf Twitter: "THREAD 1/ Our #LongCovid survey findings are now out. I want to express sincere thanks to all the participants. This study is from & for you. Apologies for the delay in reporting due to limited time & capacity but here we are (preprint, not peer reviewed) https://t.co/y7l60hqYnf https://t.co/iHSQYC1bT3" / Twitter
fsnestel·twitter.com·
(3) Dr Nisreen Alwan 🌻 auf Twitter: "THREAD 1/ Our #LongCovid survey findings are now out. I want to express sincere thanks to all the participants. This study is from & for you. Apologies for the delay in reporting due to limited time & capacity but here we are (preprint, not peer reviewed) https://t.co/y7l60hqYnf https://t.co/iHSQYC1bT3" / Twitter